UDK: 615.065:615.273.53-616.14-002

PHARMACOECONOMIC ANALYSIS OF NEW ORAL ANTICOAGULANTS IN VTE

O. V. Shatalova, V. S. Gorbatenko, A. S. Maslakov, A. S. Gerasimenko

Волгоградский государственный медицинский университет, кафедра клинической фармакологии и интенсивной терапии с курсами клинической фармакологии ФУВ, клинической аллергологии ФУВ

Abstract

The findings of pharmacoeconomic analysis of novel anticoagulants in the treatment of venous thromboembolism are presented.Rivaroxaban, apixaban and dabigatran have proved to lower health care costs as compared to conventional treatment. Budget impact analysis has demonstrated that the introduction of novel anticoagulants can reduce healthcare costs by more than 3 million rubles.

Keywords

rivaroxaban, apixaban, dabigatran, venous thromboembolism, decision trees, budget impact analysis

Contacts

Маслаков Александр Сергеевич — аспирант кафедры клинической фармакологии и интенсивной терапии, Волгоградский государственный медицинский университет, e-mail: doctor.al.87@gmail.com